
Comparative antibacterial activity of a new oral cephalosporin, BMY-28100
Author(s) -
Nai-Xun Chin,
H C Neu
Publication year - 1987
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.31.3.480
Subject(s) - microbiology and biotechnology , bacteroides fragilis , cephalosporin , cefaclor , providencia , citrobacter freundii , enterobacter , citrobacter , haemophilus influenzae , neisseria gonorrhoeae , enterococcus faecalis , klebsiella pneumoniae , listeria , biology , haemophilus parainfluenzae , escherichia coli , listeria monocytogenes , antibiotics , bacteria , biochemistry , genetics , gene
BMY-28100 is a new oral cephalosporin which had in vitro activity superior to that of cephalexin and cefaclor against staphylococci, beta-hemolytic streptococcal species, and Streptococcus pneumoniae. It inhibited beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, 50% of Streptococcus faecalis isolates, Listeria monocytogenes, and 50 to 75% of Escherichia coli and Klebsiella species at less than or equal to 8 micrograms/ml, but high producers of beta-lactamase were resistant. Enterobacter, Citrobacter, Morganella, Providencia, and Pseudomonas species and Bacteroides fragilis were resistant. BMY-28100 was more stable than cefaclor against hydrolysis by beta-lactamases.